NEUROCRINE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 132.5 USD | -0.52% |
|
-2.49% | +0.59% |
| Apr. 17 | Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test | MT |
| Apr. 16 | Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development | MT |
Chart calendar Neurocrine Biosciences, Inc.
f45c81092.aBlJZydP_4QsRsLWJRHTTG-RXMtVq7z9AUDFeUMLZcQ.MmgmEhQFqLMaBLGQSnahPB36EI5gmd2rVhC1CRlTJrQsQRFfQgCbskYArQ~d4051470194da2eda394325781179ec4
Upcoming events on Neurocrine Biosciences, Inc.
Past events on Neurocrine Biosciences, Inc.
| 2024-03-19 02:00 pm | Stifel Virtual CNS Conference |
| 2024-03-18 12:00 pm | UBS Virtual CNS Day |
| 2024-03-13 10:15 am | Barclays Global Healthcare Conference |
| 2024-03-12 08:40 am | Leerink Partners Global Biopharma Conference |
| 2024-03-05 11:10 am | TD Cowen Health Care Conference |
| 2024-02-07 08:00 am | Q4 2023 Earnings Call |
| 2024-02-07 07:00 am | Q4 2023 Earnings Release |
| 2024-01-09 12:45 pm | JPMorgan Healthcare Conference |
| 2023-12-05 01:00 pm | Analyst Day |
| 2023-11-14 10:00 am | Jefferies London Healthcare Conference |
| 2023-11-08 | NEI Congress |
| 2023-11-01 | Huntington Study Group Meeting - Poster Number # 66 |
| 2023-11-01 | Huntington Study Group Meeting - Poster Number # 62 |
| 2023-11-01 | Huntington Study Group Meeting - Poster Number # 63 |
| 2023-11-01 | Huntington Study Group Meeting - Poster Number # 65 |
| 2023-11-01 | Huntington Study Group Meeting - Poster Number # 64 |
| 2023-10-31 08:00 am | Q3 2023 Earnings Call |
| 2023-10-31 07:00 am | Q3 2023 Earnings Release |
| 2023-10-05 08:00 am | CAHtalystTM Pediatric Phase 3 Study Results Call |
| 2023-09-20 | European Society for Pediatric Endocrinology Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 788 776 1.52% | 1 046 1 058 -1.18% | 1 134 1 139 -0.47% | 1 489 1 484 0.31% | 1 887 1 885 0.1% | 2 212 |
|
EBITDA Million USD | Released Forecast Spread | 79,7 114 -30.31% | 192 178 7.55% | 131 232 -43.66% | 264 336 -21.3% | 269 281 -4.33% | 561 |
|
EBIT Million USD | Released Forecast Spread | 72,3 105 -31.23% | 163 162 0.44% | 103 209 -51.06% | 249 289 -13.9% | 251 258 -2.84% | 592 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 46,5 87,9 -47.11% | 107 129 -17.29% | 101 181 -43.99% | 214 241 -11.43% | 332 296 12.11% | 637 |
|
Net income Million USD | Released Forecast Spread | 37,0 78,4 -52.81% | 407 121 236.66% | 89,6 148 -39.37% | 155 188 -17.63% | 250 225 11.11% | 490 |
|
EPS USD | Released Forecast Spread | 0,39 0,82 -52.34% | 4,16 1,23 238.86% | 0,92 1,51 -39.1% | 1,56 1,88 -17.15% | 2,47 2,22 11.3% | 4,72 |
| Announcement Date | 04/02/20 | 04/02/21 | 11/02/22 | 06/02/23 | 07/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 312 318 -1.8% | 311 304 2.15% | 378 343 10.12% | 388 377 2.96% | 412 409 0.74% | 420 409 2.78% | 453 448 1.05% | 499 479 4.13% | 515 518 -0.62% | 514 | 546 | 572 | 584 | 548 |
|
EBITDA Million USD | Released Forecast Spread | -28,9 76,6 -137.73% | 6,80 43,3 -84.3% | 59,0 75,6 -21.96% | 91,8 109 -16.04% | 107 155 -30.67% | -109 42,8 -355.18% | 78,7 126 -37.5% | 144 147 -1.74% | 155 149 4.23% | 127 | 135 | 144 | 134 | |
|
EBIT Million USD | Released Forecast Spread | -36,3 70,8 -151.3% | 3,10 39,1 -92.07% | 54,7 66,7 -17.94% | 87,8 96,8 -9.28% | 103 136 -23.91% | -114 14,7 -874.64% | 73,6 99,5 -26.06% | 141 125 12.9% | 150 154 -2.64% | 115 | 144 | 159 | 162 | 117 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -13,8 65,4 -121.11% | 21,4 33,6 -36.38% | -23,3 61,7 -137.75% | 97,9 89,2 9.71% | 118 135 -12.69% | -103 33,1 -412.49% | 122 98,0 24.07% | 116 132 -12.2% | 198 159 24.47% | 125 | 155 | 172 | 177 | 137 |
|
Net income Million USD | Released Forecast Spread | -7,30 50,4 -114.49% | 13,9 30,8 -54.88% | -16,9 58,1 -129.08% | 68,5 76,2 -10.08% | 89,0 118 -24.66% | -76,6 8,27 -1026.71% | 95,5 75,4 26.62% | 83,1 97,8 -15.04% | 148 115 28.34% | 99,4 | 122 | 131 | 135 | 104 |
|
EPS USD | Released Forecast Spread | -0,08 0,52 -115.47% | 0,14 0,33 -57.17% | -0,18 0,62 -128.85% | 0,69 0,79 -13.19% | 0,88 1,15 -23.33% | -0,79 0,04 -2143.98% | 0,95 0,77 23.93% | 0,82 0,97 -15.1% | 1,44 1,12 28.46% | 0,98 | 1,16 | 1,26 | 1,27 | 1,01 |
| Announcement Date | 11/02/22 | 04/05/22 | 04/08/22 | 01/11/22 | 06/02/23 | 03/05/23 | 01/08/23 | 31/10/23 | 07/02/24 | - | - | - | - | - |
More events
Past sector events for Neurocrine Biosciences, Inc.
| 2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NBIX Stock
- Calendar Neurocrine Biosciences, Inc.
